4,200 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Bought by Jefferies Financial Group Inc.

Key Points

Error: Response status code does not indicate success: 500 (Internal Server Error).

Jefferies Financial Group Inc. purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 4,200 shares of the company's stock, valued at approximately $757,000.

Other hedge funds have also made changes to their positions in the company. Crossmark Global Holdings Inc. lifted its holdings in shares of Krystal Biotech by 2.7% in the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock worth $427,000 after acquiring an additional 63 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Krystal Biotech by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after acquiring an additional 82 shares during the last quarter. Xponance Inc. lifted its holdings in shares of Krystal Biotech by 4.9% in the 1st quarter. Xponance Inc. now owns 1,873 shares of the company's stock worth $338,000 after acquiring an additional 88 shares during the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in shares of Krystal Biotech by 6.7% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock worth $273,000 after acquiring an additional 95 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its holdings in shares of Krystal Biotech by 0.6% in the 1st quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock worth $2,881,000 after acquiring an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Price Performance

Shares of KRYS traded up $2.56 during midday trading on Friday, reaching $138.66. The stock had a trading volume of 332,066 shares, compared to its average volume of 422,365. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84. The company's fifty day simple moving average is $141.94 and its two-hundred day simple moving average is $155.36. The company has a market cap of $4.01 billion, a price-to-earnings ratio of 28.18 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th. Citigroup restated a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a report on Tuesday. Guggenheim reduced their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Bank of America reduced their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, Chardan Capital reiterated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has an average rating of "Buy" and an average price target of $210.22.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).